These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
715 related articles for article (PubMed ID: 21162646)
1. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy. Senna GE; Calderon M; Milani M Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646 [TBL] [Abstract][Full Text] [Related]
2. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937 [TBL] [Abstract][Full Text] [Related]
3. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet. Nelson H; Lehmann L; Blaiss MS Curr Med Res Opin; 2012 Jun; 28(6):1043-51. PubMed ID: 22502864 [TBL] [Abstract][Full Text] [Related]
4. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Ibañez MD; Kaiser F; Knecht R; Armentia A; Schöpfer H; Tholstrup B; Bufe A Pediatr Allergy Immunol; 2007 Sep; 18(6):516-22. PubMed ID: 17680910 [TBL] [Abstract][Full Text] [Related]
5. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092 [TBL] [Abstract][Full Text] [Related]
6. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Dahl R; Stender A; Rak S Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194 [TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons - the GRAAL trial. Wessel F; Chartier A; Meunier JP; Magnan A Clin Drug Investig; 2012 Jul; 32(7):451-63. PubMed ID: 22594491 [TBL] [Abstract][Full Text] [Related]
8. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Durham SR; Riis B Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937 [TBL] [Abstract][Full Text] [Related]
10. Effect of AIT in children including potential to prevent the development of asthma. Valovirta E Allergy; 2011 Jul; 66 Suppl 95():53-4. PubMed ID: 21668856 [TBL] [Abstract][Full Text] [Related]
11. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. Dahl R; Kapp A; Colombo G; de Monchy JG; Rak S; Emminger W; Riis B; Grønager PM; Durham SR J Allergy Clin Immunol; 2008 Feb; 121(2):512-518.e2. PubMed ID: 18155284 [TBL] [Abstract][Full Text] [Related]
12. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126 [TBL] [Abstract][Full Text] [Related]
13. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Valovirta E; Berstad AK; de Blic J; Bufe A; Eng P; Halken S; Ojeda P; Roberts G; Tommerup L; Varga EM; Winnergard I; Clin Ther; 2011 Oct; 33(10):1537-46. PubMed ID: 21999887 [TBL] [Abstract][Full Text] [Related]
14. Grazax: an oral vaccine for the treatment of grass pollen allergy (hay fever). Allison C; Fraser J Issues Emerg Health Technol; 2007 Nov; (107):1-4. PubMed ID: 18041171 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Nasser S; Vestenbaek U; Beriot-Mathiot A; Poulsen PB Allergy; 2008 Dec; 63(12):1624-9. PubMed ID: 19032235 [TBL] [Abstract][Full Text] [Related]
16. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. Durham SR; Emminger W; Kapp A; Colombo G; de Monchy JG; Rak S; Scadding GK; Andersen JS; Riis B; Dahl R J Allergy Clin Immunol; 2010 Jan; 125(1):131-8.e1-7. PubMed ID: 20109743 [TBL] [Abstract][Full Text] [Related]
17. Oralair(®): a causal treatment for grass pollen-induced allergic rhinoconjunctivitis. Köberlein J; Mösges R Immunotherapy; 2013 Jan; 5(1):13-21. PubMed ID: 23256794 [TBL] [Abstract][Full Text] [Related]
18. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis]. Wolthers OD; Høst A; Frederiksen B; Halken S Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576 [TBL] [Abstract][Full Text] [Related]
19. Postmarketing study for assessment of tolerability of a grass allergen immunotherapy tablet (GRAZAX) in patients with rhinitis or rhinoconjunctivitis. Armentia A; Carballada F; Carretero P; de Paz S; Lobera T; Marcos C; Martínez JC; Rodríguez I; Soto T; Venturini M; de la Torre F J Investig Allergol Clin Immunol; 2012; 22(7):485-90. PubMed ID: 23397670 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective. Bachert C; Vestenbaek U; Christensen J; Griffiths UK; Poulsen PB Clin Exp Allergy; 2007 May; 37(5):772-9. PubMed ID: 17456225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]